← Back to Clinical Trials
Recruiting NCT05786664

NCT05786664 Breast Cancer Survivorship Biorepository

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05786664
Status Recruiting
Phase
Sponsor University of Southern California
Condition Anatomic Stage I Breast Cancer AJCC v8
Study Type OBSERVATIONAL
Enrollment 1,300 participants
Start Date 2022-04-11
Primary Completion 2027-04-11

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Biospecimen CollectionElectronic Health Record ReviewQuality-of-Life Assessment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,300 participants in total. It began in 2022-04-11 with a primary completion date of 2027-04-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study collects blood samples as well as clinical and self-report data from stage I-III breast cancer survivors to create a biorepository for future use. The creation of this biorepository will allow for future research into links between individual, molecular, and genomic signatures and cancer outcomes.

Eligibility Criteria

Inclusion Criteria: * Women of all racial and ethnic groups 18 years of age or older * Women with a diagnosis of invasive breast cancer (stages I-III) within the past 7 years * Women who have completed active treatment for breast cancer (surgery, chemotherapy, HER2-directed therapy and radiation) * Prior participation on clinical trials is allowed Exclusion Criteria: * Current receipt of interventional clinical trial participation * Stage IV (metastatic) cancer * Prior history of recurrence (except recurrence following ductal carcinoma in situ) * Inability to give informed consent * Unable to speak English, Spanish, Chinese, or Korean

Contact & Investigator

Central Contact

Audrey Saghian, MPH

✉ amsaghia@usc.edu

📞 323-865-6086

Principal Investigator

Bodour Salhia, PhD

PRINCIPAL INVESTIGATOR

University of Southern California

Frequently Asked Questions

Who can join the NCT05786664 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Anatomic Stage I Breast Cancer AJCC v8. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05786664 currently recruiting?

Yes, NCT05786664 is actively recruiting participants. Contact the research team at amsaghia@usc.edu for enrollment information.

Where is the NCT05786664 trial being conducted?

This trial is being conducted at Los Angeles, United States.

Who is sponsoring the NCT05786664 clinical trial?

NCT05786664 is sponsored by University of Southern California. The principal investigator is Bodour Salhia, PhD at University of Southern California. The trial plans to enroll 1,300 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology